Danimer Scientific Inc

Danimer Scientific — Q3 2022 Earnings Presentation

11 slides from Danimer Scientific's earnings presentation, Nov 8, 2022

  1. Slide 1: Third Quarter 2022 Earnings Presentation

    Third Quarter 2022 Earnings Presentation November 8, 2022

  2. Slide 2: Disclaimer

    Disclaimer This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitatio

  3. Slide 3: Danimer's Strategic Priorities

    Danimer’s Strategic Priorities Expand Capacity to Achieve Scale 1 2 3 4 5 6 Lead with Innovation to Address a Broad Range of Customer Needs Grow Customer Partnerships and Product Volume Commitments Secure Cost-Effective Inputs Attain Favorable Unit Economics to Enhance Margins Enhance Team Capabilit

  4. Slide 4: Recent Business Highlights

    Recent Business Highlights Business Highlights Continued execution of growth strategy to transform the plastics market Raised visibility of bioplastics solutions through participation at White House Summit PHA-based revenues increased by 26% YoY, representing 51% of product revenues Signed a distrib

  5. Slide 5: Customer Partnerships & Business Development Initiatives

    Customer Partnerships & Business Development Initiatives Distribution agreement with Formerra, formerly Avient, a leader in specialty polymer formulations and distribution across the globe Business Development & Partnerships Two-year partnership to develop innovative home compostable packaging Initi

  6. Slide 6: Q3 2022 Financial Summary

    Q3 2022 Financial Summary PHA-based revenues increased by 26% YoY, representing 51% of revenue vs 32% in Q3 2021 Adjusted gross profit down YoY due to combination of reduced PLA resin sales and higher fixed costs associated with increased PHA capacity Increase in SG&A and R&D spend includes a full q

  7. Slide 7: Financial Outlook

    Financial Outlook 4% PHA PHA Gross Margin Total Gross Margin SG&A & R&D as % of Sales Danimer Catalytic Technologies Profit Contribution Adjusted EBITDA 2022E Adj. EBITDA of ($45) - ($40) Million Expect 2022E Capex of $165 to $170 million(1) and year end cash balance of $60 to $65 million Change vs

  8. Slide 8: Forward Catalysts

    Forward Catalysts Continued focus on driving operational costs down as we scale production Large and growing TAM Believed to be the only PHA product offering at commercial scale production Increasing governmental regulations on single-plastic uses Demand from blue chip multinational customers Increa

  9. Slide 9: Appendix

    & danimer ~ scientific Appendix Perini ~

  10. Slide 10: EBITDA and EBITDAR Reconciliation

    EBITDA and EBITDAR Reconciliation Note: Totals may not foot due to rounding.

  11. Slide 11: Adjusted Gross Profit Reconciliation

    Adjusted Gross Profit Reconciliation Note: Totals may not foot due to rounding.

Danimer Scientific — Q3 2022 Earnings Presentation on 6ix